Article metrics

Download PDFPDF

A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis

 

Online download statistics by month:

Online download statistics by month: September 2020 to February 2021

AbstractFullPdf
Sep 202011131090288
Oct 202011101095528
Nov 2020774769229
Dec 2020481469182
Jan 2021322313146
Feb 202124023597
Total404039711470